BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $11 from $13 and keeps an Underperform rating on the shares after Myriad reported Q4 sales in line with the mid-January topline preannouncement and reiterated its FY25 guidance. The firm’s lower price target accounts for peer group multiple compression, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes
- Myriad Genetics Reports Strong Growth Amid Challenges
- Cautious Outlook for Myriad Genetics Amid Leadership Transition and Revised Growth Projections
- Myriad Genetics price target lowered to $19 from $27 at Raymond James
- Myriad Genetics price target lowered to $16 from $17 at TD Cowen